Print this page
Back to Web version of article
GMHC Treatment Issues
Table of Contents, May, 1998
- NTZ Set Back
FDA Advisory Committee votes against approval of NTZ for cryptosporidiosis-related diarrhea
- Heart Disease and HIV
Protease inhibitors add extra risk due to their effect on raising lipid levels, but many other factors are at play
- Treatment Briefs
Efavirenz and Fortovase do not mix, Pharmacia & Upjohn seeks a buyer for its HIV drugs while Glaxo buys a new line of NNRTIs, Viagra and protease inhibitors, topical KS treatment goes to the FDA
Prophylactic treatment following sexual exposure to HIV
- Just in Time for the World AIDS Conference
Some tips on adjusting protease inhibitor regimens to other time zones
This article was provided by Gay Men's Health Crisis. It is a part of the publication GMHC Treatment Issues.
You can find this article online by typing this address into your Web browser:
General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.